Waud Capital Partners Expands Healthcare Focus with Mopec Group Acquisition

On January 6, 2025, Waud Capital Partners announced its latest acquisition of Mopec Group, a company dedicated to serving the needs of pathology and laboratory markets. This strategic purchase marks a significant milestone for Waud Capital, a private equity firm that has carved a niche for itself in the healthcare and software sectors. The deal involves acquiring Mopec from Blackford Capital, based in Michigan, a firm known for targeting lower middle market opportunities.

Mopec Group: A Leader in Pathology Solutions

Founded in 1992 and headquartered in Madison Heights, Michigan, Mopec Group has established itself as a premier supplier of high-quality anatomical and forensic pathology equipment and services. The company’s mission focuses on enhancing diagnostic accuracy and safety within the medical field, underscoring the importance of quality products in healthcare.

According to Francis X. Dirksmeier, CEO of Mopec Group, this acquisition represents a pivotal moment in the company's journey. He expressed optimism, stating that the partnership with Waud Capital will not only bolster their current capabilities but will also open new avenues for innovation and growth. Dirksmeier believes that the investment aligns with Mopec’s mission to improve disease treatment outcomes through cutting-edge solutions.

Leadership and Vision

As part of the acquisition, Brad Staley, an Executive Partner at Waud Capital, will step in as Executive Chairman of Mopec Group's Board of Directors. With over 25 years of experience in healthcare and technology, Staley is known for his expertise in scaling organizations and optimizing supply chains. He emphasized Mopec’s strong brand equity and is excited about the potential for continued growth in its core markets.

The increasing demand for precise healthcare solutions, driven by a growing incidence of diseases, has reinforced the necessity for value-added partners like Mopec. Mike Lehman, a Principal at Waud Capital, noted the company’s unique approach in catering to pathology and laboratory customers, highlighting Mopec’s ability to build sustainable, long-term partnerships.

A Strategic Investment

Kyle Lattner, a Waud Capital Partner, outlined that the acquisition of Mopec fits seamlessly into their Medical Device Supply Services campaign. The strategy focuses on investing in companies where there is strong executive leadership and real conviction in the product offering. This marks a continuation of Waud Capital’s commitment to empowering organizations in the healthcare sector with the resources needed for growth.

Stout Capital served as the financial advisor for Waud Capital in this transaction, while Kirkland Ellis LLP acted as their legal counsel. The advisory team for Blackford Capital and Mopec included Piper Sandler Co. and Varnum LLP, ensuring a well-coordinated transition process.

Future Prospects

As Waud Capital Partners forges ahead with its vision for Mopec Group, the emphasis will be on enhancing their product offerings and service capabilities. This acquisition signifies not only growth for Waud Capital but also a crucial expansion of services that directly impact healthcare providers and patients. With a strong commitment to innovation and excellence, both Waud Capital and Mopec are positioned to make substantial contributions to health care and laboratory services in the years to come.

For more information about Mopec Group and its offerings, visit www.mopec.com. You can learn about Waud Capital Partners and their investment strategy at www.waudcapital.com.